Azitra (AZTR) Non-cash Items (2022 - 2023)
Azitra (AZTR) reported Non-cash Items of $108300.0 for Q4 2023, down 58.94% on a YoY basis from $263743.0 in Q4 2022, and down 66.55% quarter-over-quarter from $323736.0 in Q3 2023.
Azitra (AZTR) Non-cash Items (2022 - 2023) Analysis & Trends
Azitra has reported Non-cash Items for 2 years, with the latest figure at $108300.0 in Q4 2023.
- For the quarter ending Q4 2023, Non-cash Items fell 58.94% year-over-year to $108300.0; the trailing twelve-month figure through Dec 2023 stood at $108300.0 (down 58.94% YoY), and the FY2023 full-year result was $108300.0, down 58.94% from the prior year.
- Non-cash Items for Q4 2023 stood at $108300.0, down from $323736.0 in the prior quarter.
- The five-year high for Non-cash Items was $323736.0 in Q3 2023, with the low at $11467.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Azitra | 20,900.00 | 20,900.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 108,300.00 |
| Dec 31, 2023 | 108,300.00 |
| Sep 30, 2023 | 323,736.00 |
| Sep 30, 2023 | 323,736.00 |
| Jun 30, 2023 | 198,290.00 |
| Jun 30, 2023 | 198,290.00 |
| Dec 31, 2022 | 263,743.00 |
| Dec 31, 2022 | 263,743.00 |
| Sep 30, 2022 | 11,467.00 |
| Sep 30, 2022 | 11,467.00 |
| Jun 30, 2022 | 263,743.00 |
| Jun 30, 2022 | 263,743.00 |